Abstract
Background: A rare type of cutaneous adverse drug reaction (CADR), lichenoid drug eruption (LDE), can be associated with ethambutol.
Case Report: A 60-year-old woman with spinal tuberculosis received multiple anti-TB medications and developed rashes after 3 months of the treatments. A skin biopsy from the posterior auricular area confirmed lichenoid dermatitis, and the Naranjo causality assessment indicated ethambutol as a probable cause of LDE in the patient. The rashes slowly improved after discontinuation of ethambutol. Unfortunately, the residual of brown hyperpigmentation on the body still persisted for over 16 months.
Conclusion: The medications were reduced to isoniazid 300 mg/day and rifampicin 450 mg /day as planned for another 3 months. This case report points out the essentials of early recognition of ethambutol LDE by health care professionals.
Keywords: Case report, ethambutol, lichenoid drug eruption, lichen planus, cutaneous adverse drug reaction (CADR), tuberculosis (TB), LDE.
Current Drug Safety
Title:Ethambutol Induced Lichenoid Drug Eruption: A Case Report
Volume: 16 Issue: 3
Author(s): Thitaree Yuyaem, Patcharaporn Sudchada*, Chutika Srisuttiyakorn, Jirapan Juntawong, Naruemon Khanngern, Natwara Watcharapokin and Pitchayakorn Chansangiam
Affiliation:
- Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok,Thailand
Keywords: Case report, ethambutol, lichenoid drug eruption, lichen planus, cutaneous adverse drug reaction (CADR), tuberculosis (TB), LDE.
Abstract:
Background: A rare type of cutaneous adverse drug reaction (CADR), lichenoid drug eruption (LDE), can be associated with ethambutol.
Case Report: A 60-year-old woman with spinal tuberculosis received multiple anti-TB medications and developed rashes after 3 months of the treatments. A skin biopsy from the posterior auricular area confirmed lichenoid dermatitis, and the Naranjo causality assessment indicated ethambutol as a probable cause of LDE in the patient. The rashes slowly improved after discontinuation of ethambutol. Unfortunately, the residual of brown hyperpigmentation on the body still persisted for over 16 months.
Conclusion: The medications were reduced to isoniazid 300 mg/day and rifampicin 450 mg /day as planned for another 3 months. This case report points out the essentials of early recognition of ethambutol LDE by health care professionals.
Export Options
About this article
Cite this article as:
Yuyaem Thitaree , Sudchada Patcharaporn *, Srisuttiyakorn Chutika , Juntawong Jirapan , Khanngern Naruemon , Watcharapokin Natwara and Chansangiam Pitchayakorn, Ethambutol Induced Lichenoid Drug Eruption: A Case Report, Current Drug Safety 2021; 16 (3) . https://dx.doi.org/10.2174/1574886315666201217095950
DOI https://dx.doi.org/10.2174/1574886315666201217095950 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treponema, Iron and Neurodegeneration
Current Alzheimer Research Enzalutamide: A Novel Anti-androgen with Prolonged Survival Rate in CRPC Patients
Mini-Reviews in Medicinal Chemistry The Involvement of PPARs in the Causes, Consequences and Mechanisms for Correction of Cardiac Lipotoxicity and Oxidative Stress
Current Molecular Pharmacology Clinical Evaluation of Natural History of Peyronie’s Disease: Our Experience, Old Myths and New Certainties
Inflammation & Allergy - Drug Targets (Discontinued) Biology-Oriented Synthesis (BIOS) of Piperine Derivatives and their Comparative Analgesic and Antiinflammatory Activities
Medicinal Chemistry Small Peptide Radiopharmaceuticals in the Imaging of Acute Thrombus
Current Pharmaceutical Design Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Functional Characterization of Chitin and Chitosan
Current Chemical Biology Plant Coumestans: Recent Advances and Future Perspectives in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Design, Synthesis and QSAR Studies on a Series of 2, 5-Disubstituted- 1,3,4-oxadiazole Derivatives of Diclofenac and Naproxen for Analgesic and Anti-inflammatory Activity
Medicinal Chemistry Role of Metalloproteinases in Tendon Pathophysiology
Mini-Reviews in Medicinal Chemistry Clozapine Safety, 40 Years Later
Current Drug Safety Microbe-Host Interactions: Structure and Role of Gram-Negative Bacterial Porins
Current Protein & Peptide Science Insulin Resistance-Induced Hypertension and a Role of Perivascular CGRPergic Nerves
Current Protein & Peptide Science Hypersensitivity to Hymenoptera Venom: Advances in Diagnosis and Implications for Treatment
Recent Patents on Inflammation & Allergy Drug Discovery Nocistatin: Milestone of One Decade of Research
Current Pharmaceutical Design Etiological and Biological Aspects of Cigarette Smoking in Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Synthesis of Cinnamyl and Caffeoyl Derivatives of Cucurbitacin-Eglycoside Isolated from Citrullus colocynthis Fruits and their Structures Antioxidant and Anti-inflammatory Activities Relationship
Current Pharmaceutical Biotechnology Selected Phytochemicals to Combat Lungs Injury: Natural Care
Combinatorial Chemistry & High Throughput Screening FoxO3a Governs Early Microglial Proliferation and Employs Mitochondrial Depolarization with Caspase 3, 8, and 9 Cleavage During Oxidant Induced Apoptosis
Current Neurovascular Research